Your browser doesn't support javascript.
Antibody duration after infection from SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey.
Swartz, Michael D; DeSantis, Stacia M; Yaseen, Ashraf; Brito, Frances A; Valerio-Shewmaker, Melissa A; Messiah, Sarah E; Leon-Novelo, Luis G; Kohl, Harold W; Pinzon-Gomez, Cesar L; Hao, Tianyao; Zhang, Shiming; Talebi, Yashar; Yoo, Joy; Ross, Jessica R; Gonzalez, Michael O; Wu, Leqing; Kelder, Steven H; Silberman, Mark; Tuzo, Samantha; Pont, Stephen J; Shuford, Jennifer A; Lakey, David; Boerwinkle, Eric.
  • Swartz MD; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, TX, USA.
  • DeSantis SM; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, TX, USA.
  • Yaseen A; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, TX, USA.
  • Brito FA; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, TX, USA.
  • Valerio-Shewmaker MA; The University of Texas Health Science Center in Houston, School of Public Health in Brownsville, Brownsville, TX, USA.
  • Messiah SE; The University of Texas Health Science Center in Houston, School of Public Health in Dallas, Dallas, TX, USA.
  • Leon-Novelo LG; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, TX, USA.
  • Kohl HW; The University of Texas Health Science Center in Houston, School of Public Health in Austin, Austin, TX, USA.
  • Pinzon-Gomez CL; The University of Texas at Austin, Austin, TX, USA.
  • Hao T; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, TX, USA.
  • Zhang S; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, TX, USA.
  • Talebi Y; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, TX, USA.
  • Yoo J; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, TX, USA.
  • Ross JR; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, TX, USA.
  • Gonzalez MO; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, TX, USA.
  • Wu L; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, TX, USA.
  • Kelder SH; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, TX, USA.
  • Silberman M; The University of Texas Health Science Center in Houston, School of Public Health in Austin, Austin, TX, USA.
  • Tuzo S; Clinical Pathology Laboratories, Austin, TX, USA.
  • Pont SJ; Clinical Pathology Laboratories, Austin, TX, USA.
  • Shuford JA; Texas Department of State Health Services, Austin, TX, USA.
  • Lakey D; Texas Department of State Health Services, Austin, TX, USA.
  • Boerwinkle E; University of Texas System, Austin, TX, USA.
J Infect Dis ; 2022 May 06.
Article in English | MEDLINE | ID: covidwho-2245564
ABSTRACT
Understanding the duration of antibodies to the SARS-CoV-2 virus that causes COVID-19 is important to controlling the current pandemic. Participants from the Texas Coronavirus Antibody REsponse Survey (Texas CARES) with at least one nucleocapsid protein antibody test were selected for a longitudinal analysis of antibody duration. A linear mixed model was fit to data from participants (n= 4,553) with one to three antibody tests over 11 months (10/1/2020-9/16/2021), and models fit showed that expected antibody response after COVID-19 infection robustly increases for 100 days post-infection, and predicts individuals may remain antibody positive from natural infection beyond 500 days, depending on age, body mass index, smoking or vaping use, and disease severity (hospitalized or not; symptomatic or not).
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Infdis